Compounded bioidentical hormone therapy (cBHRT)
Compounded bioidentical hormone therapy (cBHRT) supplies hormones structurally identical to endogenous ones in individually compounded creams, troches, capsules or pellets, outside the medicines regulatory pathway. The British Menopause Society and the 2020 National Academies review both advise against routine use, citing purity and potency concerns and insufficient evidence that compounded progesterone doses protect the endometrium. The Atlas records it as a value distinct from body-identical hormone therapy: the two are chemically identical and regulatorily opposite. It concentrates in private hormone clinics in London, German-speaking Europe and the Gulf. Evidence tier: limited.
What it is
Compounded bioidentical hormone therapy, cBHRT, uses hormones structurally identical to those the body produces, but formulated to individual prescription by a compounding pharmacy rather than supplied as a regulator-approved product. Preparations are commonly creams, troches, capsules or subcutaneous pellets, and are frequently dosed against salivary or serum hormone panels. The British Menopause Society distinguishes cBHRT from regulated bioidentical hormone replacement therapy and does not recommend it, citing purity, potency and safety concerns and, specifically, a lack of evidence that the progesterone doses used in compounded preparations provide adequate endometrial protection. The 2020 National Academies review reached a similar conclusion in the United States, noting that the FDA does not review or approve compounded preparations for safety, quality or effectiveness, and recommending that use be restricted to defined clinical circumstances. The Atlas records this as a value distinct from body-identical hormone therapy and never as a synonym for it. The chemistry is the same. The regulatory status is not, and that difference is the entire content of the term.
Who it is for
The stated clinical case for compounding is narrow: patients with documented allergy or intolerance to an excipient in every available licensed product, or who need a dose or route no licensed product supplies. Both the British Menopause Society and the National Academies hold that this population is small and that most women seeking bioidentical hormones can be served by licensed products. Women relying on compounded progesterone for endometrial protection warrant particular caution, since this is the specific safety gap the guidance names. In practice the market is considerably wider than the clinical case, which is why the Atlas records the term as a market fact rather than as an endorsement.
What to expect
Care usually begins with an extended consultation and a hormone panel, in some operator models including salivary testing, which mainstream guidance does not support for dose titration. A clinician specifies a formulation and a compounding pharmacy prepares it individually. Delivery is commonly a transdermal cream, a sublingual troche, a capsule or an implanted pellet. Follow-up is typically more frequent than in licensed-product pathways because dose response is less predictable. Across the Atlas the term concentrates in three places: private London hormone clinics, German-speaking practices writing bioidentisch, and Gulf and Southeast Asian longevity-adjacent operators. Pellet implants are a distinct and heavily marketed sub-form, dominant in Brazil, where they are frequently sold alongside aesthetic services; the Atlas does not treat pellet implantation as a modality and excludes operators whose menopause offer is pellets plus vaginal laser and nothing else.
History and background
Compounding is a long-standing pharmacy practice that predates modern medicines regulation, and it retains a legitimate role for genuinely individual needs. The bioidentical hormone market grew sharply after the 2002 Women's Health Initiative publication, when demand for an alternative to conjugated equine estrogens outran the licensed product range, and consumer advocacy through the 2000s established bioidentical as a marketing category in its own right. Regulatory bodies responded slowly. The 2019 British Menopause Society consensus statement drew the rBHRT and cBHRT line explicitly. The 2020 National Academies report, commissioned by the FDA, found the evidence base for compounded preparations insufficient and use substantially broader than any clinical justification supported. The market has continued to grow regardless, which is why the term earns a place in the vocabulary: it names something real and recurring that operators deliver, and recording it is what makes the regulatory distinction visible.
Worth knowing
This is the one term in the femtech branch where the Atlas records a modality that its own primary sources advise against, and it is recorded precisely so the distinction from body-identical therapy can be seen rather than blurred. The German-language market is where the ambiguity bites hardest: bioidentisch is the ordinary word in Germany and Austria for what the United Kingdom calls body-identical, so an operator using it may sit on either side of the regulatory line. Reading the word alone will misclassify clinics in both directions. The compounded market's most visible sub-form, the hormone pellet, is also the one most entangled with aesthetics: in Brazil the pellet and the vaginal laser are frequently the whole product, and that pattern is a scope signal rather than a clinical one.
Offered across the Atlas 6
Related modalities